Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban; S. L. Hauser; L. Kappos; D. L. Arnold; A. Bar-Or; G. Comi; J. de Seze; G. Giovannoni; H. -P. Hartung; B. Hemmer; F. Lublin; K. W. Rammohan; K. Selmaj; A. Traboulsee; A. Sauter; D. Masterman; P. Fontoura; S. Belachew; H. Garren; N. Mairon; P. Chin; ORATORIO Clinical Investigators; Raymond Hupperts; J. S. Wolinsky

doi:10.1056/NEJMoa1606468

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

X. Montalban, S. L. Hauser, L. Kappos, D. L. Arnold, A. Bar-Or, G. Comi, J. de Seze, G. Giovannoni, H. -P. Hartung, B. Hemmer, F. Lublin, K. W. Rammohan, K. Selmaj, A. Traboulsee, A. Sauter, D. Masterman, P. Fontoura, S. Belachew, H. Garren, N. MaironP. Chin, ORATORIO Clinical Investigators, Raymond Hupperts, J. S. Wolinsky

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	209-220
Number of pages	12
Journal	New England Journal of Medicine
Volume	376
Issue number	3
DOIs	https://doi.org/10.1056/NEJMoa1606468
Publication status	Published - 19 Jan 2017

Keywords

DOUBLE-BLIND
MULTICENTER TRIAL
CANCER-RISK
CD20
DEMYELINATION
PATHOLOGY
ANTIBODY
DAMAGE

Access to Document

10.1056/NEJMoa1606468

Cite this

Montalban, X., Hauser, S. L., Kappos, L., Arnold, D. L., Bar-Or, A., Comi, G., de Seze, J., Giovannoni, G., Hartung, H. -P., Hemmer, B., Lublin, F., Rammohan, K. W., Selmaj, K., Traboulsee, A., Sauter, A., Masterman, D., Fontoura, P., Belachew, S., Garren, H., ... Wolinsky, J. S. (2017). Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 376(3), 209-220. https://doi.org/10.1056/NEJMoa1606468

Montalban, X. ; Hauser, S. L. ; Kappos, L. ; Arnold, D. L. ; Bar-Or, A. ; Comi, G. ; de Seze, J. ; Giovannoni, G. ; Hartung, H. -P. ; Hemmer, B. ; Lublin, F. ; Rammohan, K. W. ; Selmaj, K. ; Traboulsee, A. ; Sauter, A. ; Masterman, D. ; Fontoura, P. ; Belachew, S. ; Garren, H. ; Mairon, N. ; Chin, P. ; ORATORIO Clinical Investigators ; Hupperts, Raymond ; Wolinsky, J. S. / Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. In: New England Journal of Medicine. 2017 ; Vol. 376, No. 3. pp. 209-220.

@article{ff0de377b14348649e76482de96b142a,

title = "Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis",

keywords = "DOUBLE-BLIND, MULTICENTER TRIAL, CANCER-RISK, CD20, DEMYELINATION, PATHOLOGY, ANTIBODY, DAMAGE",

author = "X. Montalban and Hauser, {S. L.} and L. Kappos and Arnold, {D. L.} and A. Bar-Or and G. Comi and {de Seze}, J. and G. Giovannoni and Hartung, {H. -P.} and B. Hemmer and F. Lublin and Rammohan, {K. W.} and K. Selmaj and A. Traboulsee and A. Sauter and D. Masterman and P. Fontoura and S. Belachew and H. Garren and N. Mairon and P. Chin and {ORATORIO Clinical Investigators} and Raymond Hupperts and Wolinsky, {J. S.}",

year = "2017",

month = jan,

day = "19",

doi = "10.1056/NEJMoa1606468",

language = "English",

volume = "376",

pages = "209--220",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "MASSACHUSETTS MEDICAL SOCIETY",

number = "3",

}

Montalban, X, Hauser, SL, Kappos, L, Arnold, DL, Bar-Or, A, Comi, G, de Seze, J, Giovannoni, G, Hartung, H-P, Hemmer, B, Lublin, F, Rammohan, KW, Selmaj, K, Traboulsee, A, Sauter, A, Masterman, D, Fontoura, P, Belachew, S, Garren, H, Mairon, N, Chin, P, ORATORIO Clinical Investigators, Hupperts, R & Wolinsky, JS 2017, 'Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis', New England Journal of Medicine, vol. 376, no. 3, pp. 209-220. https://doi.org/10.1056/NEJMoa1606468

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. / Montalban, X.; Hauser, S. L.; Kappos, L.; Arnold, D. L.; Bar-Or, A.; Comi, G.; de Seze, J.; Giovannoni, G.; Hartung, H. -P.; Hemmer, B.; Lublin, F.; Rammohan, K. W.; Selmaj, K.; Traboulsee, A.; Sauter, A.; Masterman, D.; Fontoura, P.; Belachew, S.; Garren, H.; Mairon, N.; Chin, P.; ORATORIO Clinical Investigators ; Hupperts, Raymond; Wolinsky, J. S.

In: New England Journal of Medicine, Vol. 376, No. 3, 19.01.2017, p. 209-220.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

AU - Montalban, X.

AU - Hauser, S. L.

AU - Kappos, L.

AU - Arnold, D. L.

AU - Bar-Or, A.

AU - Comi, G.

AU - de Seze, J.

AU - Giovannoni, G.

AU - Hartung, H. -P.

AU - Hemmer, B.

AU - Lublin, F.

AU - Rammohan, K. W.

AU - Selmaj, K.

AU - Traboulsee, A.

AU - Sauter, A.

AU - Masterman, D.

AU - Fontoura, P.

AU - Belachew, S.

AU - Garren, H.

AU - Mairon, N.

AU - Chin, P.

AU - ORATORIO Clinical Investigators

AU - Hupperts, Raymond

AU - Wolinsky, J. S.

PY - 2017/1/19

Y1 - 2017/1/19

KW - DOUBLE-BLIND

KW - MULTICENTER TRIAL

KW - CANCER-RISK

KW - CD20

KW - DEMYELINATION

KW - PATHOLOGY

KW - ANTIBODY

KW - DAMAGE

U2 - 10.1056/NEJMoa1606468

DO - 10.1056/NEJMoa1606468

M3 - Article

VL - 376

SP - 209

EP - 220

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 3

ER -